Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

BACKGROUND: Folate binding protein(FBP) is an immunogenic protein over-expressed in endometrial(EC) and ovarian cancer(OC). We are conducting a phase I/IIa trial of E39 (GALE 301)+GM-CSF, an HLA-A2-restricted, FBP-derived peptide vaccine to prevent recurrences in disease-free EC and OC patients. Thi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Jackson, Doreen O., Byrd, Kevin, Vreeland, Timothy J., Hale, Diane F., Herbert, Garth S., Greene, Julia M., Schneble, Erika J., Berry, John S., Trappey, Alfred F., Travis Clifton, Guy, Hardin, Mark O., Martin, Jonathan, Elkas, John C., Conrads, Thomas P., Darcy, Kathleen M., Hamilton, Chad A., Maxwell, George L., Peoples, George E.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5362533/
https://ncbi.nlm.nih.gov/pubmed/27852036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13305
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares